File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Neoadjuvant therapy with concurrent docetaxel, epirubicin, and cyclophosphamide (TEC) in high-risk HER2-negative breast cancers

TitleNeoadjuvant therapy with concurrent docetaxel, epirubicin, and cyclophosphamide (TEC) in high-risk HER2-negative breast cancers
Authors
KeywordsAnthracycline
Breast cancer
Neoadjuvant therapy
Pathologic complete response
Taxane
TEC
Issue Date2021
PublisherAdis International Ltd. The Journal's web site is located at https://www.springer.com/journal/12325
Citation
Advances in Therapy, 2021, v. 38 n. 12, p. 5752-5762 How to Cite?
AbstractIntroduction: Concurrent anthracycline and taxane is an effective and efficient way to deliver neoadjuvant chemotherapy for HER2-negative breast cancers. Data on efficacy and tolerance to 6 cycles of concurrent docetaxel, epirubicin, and cyclophosphamide (TEC) is limited. Method: All patients with HER2-negative breast cancers who received neoadjuvant TEC from January 2013 to December 2019 were reviewed. Results: A total of 71 patients [57 luminal B disease; 14 triple negative breast cancer (TNBC)] received neoadjuvant TEC with prophylactic granulocyte colony-stimulating factor (G-CSF). The pathological complete response (pCR) rate was 26.3% and 28.6% for luminal B and TNBC, respectively. With median follow-up of 48.9 months, 3 years disease-free survival was 85.9%, and 3 years overall survival was 89.6%. Non-hematological toxicities were common but the majority was grade 1 or 2. The most common grade 3 or 4 toxicity were hematological, including neutropenia (26.8%) and anemia (15.5%). There was no cardiotoxicity observed. Half of the patients had at least one dose reduction but all patients completed the planned 6 cycles and had breast surgery done. Conclusion: Six cycles of TEC with prophylactic G-CSF is an effective and tolerable neoadjuvant regime for HER2-negative breast cancers. Hematological toxicities were the most common toxicities. Although many patients required dose reduction, all patients completed treatment and there was no observed cardiotoxicity.
Persistent Identifierhttp://hdl.handle.net/10722/307903
ISSN
2020 Impact Factor: 3.845
2020 SCImago Journal Rankings: 1.097
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLi, B-
dc.contributor.authorYau, T-
dc.contributor.authorLeung, R-
dc.contributor.authorKwok, G-
dc.contributor.authorTsang, J-
dc.contributor.authorCheung, P-
dc.contributor.authorWong, TT-
dc.contributor.authorSuen, D-
dc.contributor.authorKwong, A-
dc.contributor.authorChiu, JW-
dc.date.accessioned2021-11-12T13:39:35Z-
dc.date.available2021-11-12T13:39:35Z-
dc.date.issued2021-
dc.identifier.citationAdvances in Therapy, 2021, v. 38 n. 12, p. 5752-5762-
dc.identifier.issn0741-238X-
dc.identifier.urihttp://hdl.handle.net/10722/307903-
dc.description.abstractIntroduction: Concurrent anthracycline and taxane is an effective and efficient way to deliver neoadjuvant chemotherapy for HER2-negative breast cancers. Data on efficacy and tolerance to 6 cycles of concurrent docetaxel, epirubicin, and cyclophosphamide (TEC) is limited. Method: All patients with HER2-negative breast cancers who received neoadjuvant TEC from January 2013 to December 2019 were reviewed. Results: A total of 71 patients [57 luminal B disease; 14 triple negative breast cancer (TNBC)] received neoadjuvant TEC with prophylactic granulocyte colony-stimulating factor (G-CSF). The pathological complete response (pCR) rate was 26.3% and 28.6% for luminal B and TNBC, respectively. With median follow-up of 48.9 months, 3 years disease-free survival was 85.9%, and 3 years overall survival was 89.6%. Non-hematological toxicities were common but the majority was grade 1 or 2. The most common grade 3 or 4 toxicity were hematological, including neutropenia (26.8%) and anemia (15.5%). There was no cardiotoxicity observed. Half of the patients had at least one dose reduction but all patients completed the planned 6 cycles and had breast surgery done. Conclusion: Six cycles of TEC with prophylactic G-CSF is an effective and tolerable neoadjuvant regime for HER2-negative breast cancers. Hematological toxicities were the most common toxicities. Although many patients required dose reduction, all patients completed treatment and there was no observed cardiotoxicity.-
dc.languageeng-
dc.publisherAdis International Ltd. The Journal's web site is located at https://www.springer.com/journal/12325-
dc.relation.ispartofAdvances in Therapy-
dc.subjectAnthracycline-
dc.subjectBreast cancer-
dc.subjectNeoadjuvant therapy-
dc.subjectPathologic complete response-
dc.subjectTaxane-
dc.subjectTEC-
dc.titleNeoadjuvant therapy with concurrent docetaxel, epirubicin, and cyclophosphamide (TEC) in high-risk HER2-negative breast cancers-
dc.typeArticle-
dc.identifier.emailYau, T: tyaucc@hku.hk-
dc.identifier.emailCheung, P: csy802@hkucc.hku.hk-
dc.identifier.emailSuen, D: suentkd@hku.hk-
dc.identifier.emailKwong, A: avakwong@hku.hk-
dc.identifier.emailChiu, JW: jwychiu@hku.hk-
dc.identifier.authorityYau, T=rp01466-
dc.identifier.authorityKwong, A=rp01734-
dc.identifier.authorityChiu, JW=rp01917-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s12325-021-01933-1-
dc.identifier.pmid34699004-
dc.identifier.scopuseid_2-s2.0-85118167822-
dc.identifier.hkuros330150-
dc.identifier.volume38-
dc.identifier.issue12-
dc.identifier.spage5752-
dc.identifier.epage5762-
dc.identifier.isiWOS:000711349300002-
dc.publisher.placeNew Zealand-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats